Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesEndocrinologyAetna Bone Mass Measurements Coverage Update | Ope…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0134

    Bone Mass Measurements

    Customize your policy alerts

    Sign up for Aetna Policy 0134 alerts

    Get alerted when Policy 0134 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing when bone mass measurements (e.g., DXA, QCT, ultrasound) are considered medically necessary, investigational, or not indicated for Aetna members; applies to providers ordering and performing bone density testing.

    Policy Summary
    PayerAetna
    PolicyBone Mass Measurements
    Policy CodePolicy 0134
    Change TypeNo material change
    Effective DateJul 16, 1996
    Last ReviewApr 5, 2023
    Next Review DateFeb 8, 2024
    Key ActionBill covered bone density CPT/HCPCS codes only when the member meets the policy's medical necessity criteria and document rationale for repeat or alternative testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≈15Specific indications listed
    ≥2 yrsUsual repeat interval
    DEXAPreferred modality
    73%Avoided DXA with prescreen
    100+References cited
    04/05/2023Last review

    Coverage Criteria for Bone Mass Measurements

    Medical Necessity Indications

    Covered when ANY of the following are met:

    Any single qualifying indication: Individuals being monitored to assess response to osteoporosis drug therapy (monitoring response covered only with dual-energy x-ray absorptiometry/DXA); individuals receiving or expected to receive glucocorticoid therapy equivalent to ≥5 mg prednisone per day for >3 months; individuals on long-term anticonvulsant therapy; individuals on long-term aromatase inhibitor therapy; individuals with celiac sprue; individuals with primary hyperparathyroidism; individuals with vertebral abnormalities on x‑ray indicative of osteoporosis/osteopenia/vertebral fracture; men >50 years with specific risk factors for osteoporosis (covered only when preventive services benefits apply); men with hypogonadism or receiving androgen deprivation treatment; individuals with non‑traumatic (fragility) fractures; screening of men >70 years (covered only when preventive services benefits apply); screening of estrogen‑deficient (peri- or post‑menopausal) women (covered only when preventive services benefits apply); women on long‑term (>2 years) Depo‑Provera therapy; women with hyperthyroidism; women with Turner syndrome

    Monitoring response to osteoporosis drug therapy is covered only by DXA.

    Repeat Measurement Exceptions

    More frequent bone mass measurements are allowed when ALL of the following contexts are present (one or more may apply):

    Policy Summary
    PayerAetna
    PolicyBone Mass Measurements
    Policy CodePolicy 0134
    Change TypeNo material change
    Effective DateJul 16, 1996
    Last ReviewApr 5, 2023
    Next Review DateFeb 8, 2024
    Key ActionBill covered bone density CPT/HCPCS codes only when the member meets the policy's medical necessity criteria and document rationale for repeat or alternative testing.
    SourceLink
    On This Page
    Coverage Criteria for Bone Mass MeasurementsCoding References and Key ValuesProvider Actions, Documentation, and BillingBackground and Evidence SummaryDefinitions and Abbreviations
    Allowed earlier repeat testing contexts: Confirmatory baseline measurement when the initial test used a different technique than the proposed monitoring method; monitoring of individuals on long‑term glucocorticoid therapy or long‑term anticonvulsant therapy (>3 months); monitoring of individuals with uncorrected primary hyperparathyroidism

    Repeat testing is otherwise usually not indicated more frequently than once every 2 years.

    Simultaneous Axial and Appendicular Measurements

    Simultaneous axial and appendicular measurements covered only when ANY of the following are met:

    Simultaneous axial and appendicular coverage: An axial (central) scan to obtain a baseline for monitoring when osteoporosis is identified on an appendicular (peripheral) scan; appendicular measurements when artifacts obscure axial skeleton measurement; member diagnosed with uncorrected primary hyperparathyroidism

    Simultaneous axial and appendicular measurements have no proven value for other indications.

    Permitted Measurement Methods

    Established/covered measurement methods:

    Established methods: Dual‑energy X‑ray absorptiometry (DEXA/DXA); quantitative computed tomography (QCT); radiographic absorptiometry (photodensitometry); single energy X‑ray absorptiometry (SEXA); ultrasound bone mineral density studies (e.g., Achilles/Bone Sonometer, Sahara, SoundScan); vertebral fracture assessment (VFA) with DXA as an adjunct to BMD measurement to calculate FRAX; trabecular bone score (TBS) for fracture‑risk evaluation

    Certain listed modalities (eg, DPA, DXL, SPA, pulse‑echo ultrasound/Bindex) are considered experimental/investigational and not covered.

    Evidence-informed coverage considerations

    Coverage considerations informed by evidence and guideline excerpts in this document segment:

    General timing and frequency: Annual DXA screening is not supported by clinical data; typical precision error (≈2–3%) and expected annual bone loss (≈1–2%) imply the minimum interval to document true bone loss is approximately 3.7–6 years.interval 3.7-6 years

    Ehrlichman and Holohan (1996) analysis.

    Populations recommended for DXA: USPSTF recommends screening women aged ≥65 and younger women whose fracture risk equals that of a 65‑year‑old white woman; guidelines recommend DXA for men at increased risk who are candidates for drug therapy (risk factors include age >70, low BMI, significant weight loss, inactivity, prolonged corticosteroid use, prior fracture, androgen deprivation).age and risk‑factor criteria per guideline

    USPSTF (2011); ACP (Qaseem et al, 2008).

    CKD/Renal osteodystrophy: BMD measurements do not reliably differentiate uremic bone disease or predict fracture risk in CKD (particularly stages 4–5); clinicians should not routinely order BMD testing in CKD patients as it currently does not provide useful information for therapeutic decisions.CKD stage 4-5 context

    Jamal (2010) and Ehrlichman and Holohan (1996).

    Use of peripheral or ultrasound methods as prescreen: Peripheral techniques (eg, DXL/Calscan, calcaneal ultrasound) and pulse‑echo ultrasonometry (Bindex) may be useful as prescreen tools to identify persons who need central DXA; performance is device‑ and population‑specific — pulse‑echo studies estimated avoiding follow‑up DXA in ~69–73% while detecting hip osteoporosis with ~80–82% sensitivity.device‑specific thresholds; sensitivity ~80-82%

    Karjalainen et al (2016); Schousboe et al (2017); de Klerk et al (2009).

    Monitoring during therapy: Some specialty guidance (eg, male hypogonadism) recommends repeating BMD at 6 and 12 months after starting testosterone replacement therapy and then annually if abnormal; routine yearly DXA generally is not supported by the broader evidence base.repeat at 6 and 12 months then annually per guideline

    European Association of Urology (Dohle et al, 2012).

    Summary conclusions (evidence to-date)

    Key conclusions relevant to clinical utility and potential coverage implications:

    FEA and HR‑pQCT evidence: HR‑pQCT micro‑architectural parameters improved fracture discrimination compared with areal BMD; addition of FEA parameters provided minimal incremental benefit in the Hertfordshire cohort (n≈359).

    Westbury et al (2019).

    AI triage tools: HealthVCF (FDA 510(k) K192901) is cleared for prioritization/triage of CT studies for suspected vertebral compression fractures but provides notification only; final diagnosis requires clinician review and there are no published peer‑reviewed studies demonstrating improved patient outcomes from its use.

    FDA 510(k) summary and policy background.

    Repeat DXA: A second BMD assessment ≈3 years after baseline did not meaningfully improve discrimination of future hip or major osteoporotic fractures beyond baseline BMD alone; routine repeat testing at 3 years is not supported.3 years

    WHI cohort analysis (mean follow‑up ~9 years).

    Tomosynthesis and trabecular analysis: Tomosynthesis‑derived trabecular indices combined with BMD correlated more strongly with CT‑based FEA failure load than BMD alone in small diabetes cohorts, suggesting potential adjunctive value that requires further validation.

    Small preliminary studies; further validation needed.

    Trabecular Bone Score (TBS): TBS provides information on bone micro‑architecture and may improve fracture risk prediction and can be incorporated into FRAX; alternative lumbar vertebra combinations (eg, L1‑L3) may perform comparably in some datasets but need further validation.

    TBS evidence summaries.

    Skin autofluorescence (SAF) for AGEs: SAF measurements correlate with AGE accumulation and are associated with lower BMD and higher prevalence of low bone density/osteoporosis and major osteoporotic fractures in diabetic cohorts, but prospective validation and assessment of clinical utility are lacking.

    Multiple studies (n up to ~1,214); causation and outcome impact not established.

    Bone mass measurement for indications other than those specifically listed in the policy (for example, evaluation of osteoporosis or osteoporotic fractures in persons with schizophrenia who are on antipsychotic medications, or routine monitoring of individuals receiving antidepressant therapy) is considered experimental and investigational because the effectiveness of these approaches has not been established. The policy explicitly lists these and other modalities (DPA, DXL, SPA, pulse-echo ultrasound) as investigational when used for such off‑label indications.

    Routine bone mineral density (BMD) testing in patients with chronic kidney disease, particularly those with CKD stages 4 and 5, is not supported. The evidence cited indicates that BMD measurements do not reliably differentiate uremic bone disease or predict fracture risk in renal osteodystrophy, and thus currently do not provide useful information to support therapeutic decisions in these patients; clinicians should not routinely order BMD testing in CKD patients.

    Finite element analysis (FEA) using QCT-derived models can estimate bone strength and has predictive value in research settings, but FEA cannot be used to diagnose osteoporosis, initiate therapy, or monitor therapy. These techniques remain primarily research tools and their role in routine clinical practice has not been defined.

    The referenced sections summarize research findings (for example, associations of skin autofluorescence [SAF] or urinary phthalate biomarkers with lower BMD or fracture risk) and emphasize limitations such as lack of causal proof, limited generalizability, and need for prospective validation. These excerpts do not themselves establish explicit coverage exclusions but indicate that SAF measurement and urinary phthalate testing are investigational pending further confirmatory studies.

    Clinical Policy Bulletins are intended to assist in administering plan benefits but are not contracts and do not replace plan provisions. Actual coverage determinations depend on the member’s specific plan provisions; the policy is a partial description and providers should rely on plan terms when determining coverage.

    Radiological computer-assisted prioritization/AI software (for example, HealthVCF) is described as a triage and prioritization tool for flagging suspected vertebral compression fractures on chest or abdominal CTs. Such tools are not medically necessary as replacements for clinician evaluation because they do not provide diagnostic confirmation and final interpretation must rest with the treating clinician.

    Yearly densitometry (annual DXA) is unlikely to be clinically indicated given typical measurement precision and expected rates of bone loss. Precision errors are commonly in the 2–3% range while annual bone loss is usually 1–2%, yielding a minimum interval to document true bone loss on the order of approximately 3.7 to 6 years; there are no clinical data demonstrating improved outcomes from annual screening.

    Routine repeat DXA testing about 3 years after the initial screening in post‑menopausal patients without osteoporosis is not supported by the evidence presented. A large cohort study and guideline recommendations conclude that a second BMD assessment at 3 years did not meaningfully improve discrimination of future hip or major osteoporotic fractures beyond the baseline BMD value and therefore should not be routinely performed.

    Skin autofluorescence (SAF) as a measure of advanced glycation end‑products (AGEs) and related SAF-AGEage indices show associations with lower BMD and higher prevalence of low bone density or fractures in diabetes cohorts, but the policy notes that these findings require larger prospective studies and further validation before SAF measurement can be considered an established clinical tool.

    This portion of the policy contains background material and does not include explicit ‘not medically necessary’ statements for every modality. Where notations of investigational status or non‑supportive evidence are provided, they are meant to inform coverage decisions but do not constitute an exhaustive list of denials; plan provisions and clinical context drive final determinations.

    Coding References and Key Values

    Covered CPT Codes (when selection criteria met)CPTCovered
    76977Ultrasound bone density measurement and interpretation, peripheral site(s), any method
    77078Computerized tomography, bone mineral density study, 1 or more sites
    77080Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites
    77081Dual energy x-ray absorptiometry (DXA), bone density study, 1 or more sites
    77085Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton, including vertebral fracture assessment
    77086Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)
    77089Trabecular bone score (TBS), calculation, with interpretation and report on fracture-risk
    77090Technical preparation and transmission of data for analysis to be performed elsewhere
    77091Technical calculation only
    77092Interpretation and report on fracture-risk only by other qualified health care professional
    CPT Codes noted as not covered or investigational in specified contextsCPTNot Covered
    0508TPulse-echo ultrasound bone density measurement resulting in indicator of axial bone mineral density, tibia
    0554TBone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment and report
    0555TRetrieval and transmission of the scan data
    0556TAssessment of bone strength and fracture risk and bone mineral density
    0557TInterpretation and report
    0691TAutomated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report
    0743TBone strength and fracture risk using finite element analysis of functional data and bone mineral density (BMD), with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, measurement of bone strength and BMD and classification of any vertebral fractures, with overall fracture-risk assessment, interpretation and report
    0749TBone strength and fracture-risk assessment using digital X-ray radiogrammetry-BMD analysis; retrieval and transmission of digital X-ray data, assessment of bone strength and fracture risk and BMD, interpretation and report
    0750TDXR-BMD analysis with single-view digital X-ray of the hand
    70486Computed tomography, maxillofacial area; without contrast material [not covered for osteoporosis screening]
    1–10 of 12
    1/2
    Covered HCPCS Codes (when selection criteria met)HCPCSCovered
    G0130Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton
    Related HCPCS/J-codes (therapies referenced in indications)HCPCS
    J1050Injection, medroxyprogesterone acetate, 1 mg
    J1950Injection, leuprolide acetate (for depot suspension), per 3.75 mg
    J9202Goserelin acetate implant, per 3.6 mg
    J9217Leuprolide acetate (for depot suspension), 7.5 mg
    J9218Leuprolide acetate, per 1 mg
    J9219Leuprolide acetate implant, 65 mg
    Relevant ICD-10 Codes (covered when selection criteria met)ICD-10
    E05.00 - E05.91Thyrotoxicosis [hyperthyroidism]
    E20.0 - E20.9Hypoparathyroidism
    E28.39Other primary ovarian failure
    E29.1Testicular hypofunction
    E34.50 - E34.52Androgen insensitivity syndrome
    G40.001 - G40.919Epilepsy and recurrent seizures
    K90.0Celiac disease
    M80.011A – M80.88XSOsteoporosis with current pathological fracture
    M81.0 - M81.8Osteoporosis without current pathological fracture
    M84.411A – M84.48XSPathologic fracture, not elsewhere classified
    1–10 of 14
    1/2
    ICD-10 Codes not covered for listed indicationsICD-10Not Covered
    F20.0 - F20.9Schizophrenia
    F32.0 – F33.9Major depressive disorders
    N18.1 - N18.9Chronic kidney disease (CKD)
    New/Category III codes mentionedCPT
    Category III CPT (Bindex)AMA issued a new Category III CPT code for Bindex measurement (pulse‑echo ultrasound)
    Regulatory referencemixed
    42 CFR Part 410Medicare Program; Medicare Coverage and Payment for Bone Mass Measurements (regulatory citation referenced)
    Referenced device 510(k)mixed
    K192901FDA 510(k) number referenced for a bone densitometry device (HealthVCF)
    No explicit CPT/HCPCS/ICD-10 codes in this document segmentmixed
    No codes listed
    inv-27: Glucocorticoid therapy — threshold for coverage
    Glucocorticoid threshold>= 5 mg prednisone equivalent per day for > 3 months
    ContextIndication: members receiving (or expected to receive) long-term systemic glucocorticoid therapy
    Modality noteBone mass measurement for this indication may include established techniques listed in policy (DXA, QCT, etc.)
    inv-28: Repeat testing interval
    Usual repeat intervalUsually not more frequently than once every 2 years
    Exceptions allowing earlier repeatConfirmatory baseline when technique differs; monitoring during long-term glucocorticoid or anticonvulsant therapy (>3 months); uncorrected primary hyperparathyroidism
    DocumentationDocument rationale when more frequent monitoring is performed
    inv-29: Depo‑Provera long-term use — coverage threshold
    Depo‑Provera duration> 2 years (long-term use)
    RationaleLong-term Depo‑Provera is associated with significant BMD loss; prescribing information recommends BMD evaluation when continued >2 years
    Population concernParticular concern in adolescents/young adults due to critical bone accrual period; some loss may be partially reversible after discontinuation
    inv-30: DXA/DXL T-score thresholds used in studies
    DXA osteoporosis definitionDXA T-score <= -2.5 defines osteoporosis (WHO standard used in cited studies)
    Calscan (DXL) upper thresholdCalscan upper threshold T-score -1.3 SD used to exclude osteoporosis (high sensitivity reported)
    Calscan (DXL) lower thresholdCalscan lower threshold T-score -2.9 SD used to predict osteoporosis with high specificity
    Study performance notesDXL (Calscan) showed good reproducibility; sensitivity/specificity varied across studies vs central DXA
    inv-31: Pulse‑echo DI threshold performance
    Prescreen performanceUsing published pulse‑echo ultrasound threshold values, multi-site Density Index (DI) could avoid follow-up DXA in ~73% of women
    Detection accuracyPulse‑echo DI detected hip osteoporosis with ~80–82% sensitivity and ~81% specificity
    Clinical rolePulse‑echo ultrasonometry may be used as an initial screening/prescreen to determine need for central DXA; prospective outcome data limited

    Provider Actions, Documentation, and Billing

    Billing Rule

    Bill covered CPT/HCPCS codes when selection criteria are met

    Bill the appropriate covered CPT/HCPCS code that corresponds to the modality and clinical indication when the policy’s selection criteria are met; covered codes include central DXA, peripheral ultrasound, CT-based BMD, VFA, and TBS as listed in the policy.

    • Covered CPT/HCPCS examples: 76977, 77078, 77080, 77081, 77085, 77086, 77089, 77090–77092, and HCPCS G0130 when applicable.
    • Ensure the billed code matches the modality performed and the indication documented in the medical record.
    Prior Authorization

    Document prescreening with pulse‑echo ultrasound and act on results

    If a pulse‑echo ultrasound device (e.g., Bindex) or other peripheral ultrasound is used as an initial prescreen, document the prescreen result and the fracture‑risk assessment context (for example, FRAX); use the prescreen to determine whether referral for central DXA is needed.

    • Bindex is intended to be used alongside FRAX/QFracture to decide whether DXA referral is required.
    • Positive or indeterminate prescreen results should prompt referral for DXA per the device/study guidance.
    Note

    No prior authorization statements in background

    Background sections do not state specific prior authorization requirements for DXA or other bone mass measurements; DXA remains the referenced diagnostic standard.

    • DXA is identified as the clinical standard for diagnostic classification.
    • No PA language appears in the policy background describing mandatory authorizations.
    Prior Authorization

    Prior authorization not specified in this excerpt

    This document excerpt does not specify plan-level prior authorization rules for bone mass measurement procedures; specific PA requirements are determined by plan provisions and local payer processes.

    • The policy text contains background references and coding lists but does not impose explicit PA steps in this excerpt.
    Prior Authorization

    Prior authorization guidance references CMS and device 510(k) summaries

    Policy references CMS/Medicare guidance and device 510(k) summaries as background; whether a procedure requires prior authorization is determined by plan provisions and may refer to CMS/local coverage decisions.

    • FDA 510(k) device summaries (e.g., K192901) and regulatory citations are included for context, not as PA rules.
    • Providers should follow plan-specific prior authorization procedures where applicable.
    Step Therapy

    Use ultrasound prescreen then refer for DXA if indicated

    Use pulse‑echo ultrasonometry or other peripheral ultrasound as an initial screening step; positive or indeterminate prescreen results should lead to referral for DXA.

    • Studies reported that pulse‑echo ultrasonometry could avoid follow-up DXA in ~69–73% of women while detecting hip osteoporosis with ~80–82% sensitivity.
    • When used as a prescreen, document whether the result led to avoidance of DXA or to referral for DXA.
    Step Therapy

    No step-therapy specified for SCI-related osteoporosis in background

    The background evidence for spinal cord injury (SCI)-related osteoporosis does not specify any required therapeutic sequencing or mandatory trials; no step‑therapy requirements are stated in this extract.

    • Available studies show variable and generally low-quality evidence for interventions in SCI-related osteoporosis.
    • No policy-mandated step therapy is described for this population in the excerpt.
    Denial Risk

    Routine repeat DXA at ~3 years not supported to improve risk discrimination

    Routine short-interval repeat DXA (e.g., around 3 years) did not improve fracture‑risk discrimination beyond baseline BMD alone in the cited cohort; routine repeat testing at short intervals is not supported by this evidence.

    • The study concluded a second BMD assessment ~3 years after baseline was not associated with improved discrimination for hip or major osteoporotic fractures.
    • Consider baseline BMD when deciding on repeat testing rather than automatic short-interval repeats.
    Documentation Required

    Document rationale for repeat testing intervals (usually ≥2 years)

    Repeat bone mass measurements should generally be performed no more frequently than once every 2 years; if more frequent monitoring is done, document the specific clinical rationale.

    • Permitted reasons for earlier repeat testing include confirmatory baseline when changing technique, monitoring long-term glucocorticoid or anticonvulsant therapy (>3 months), or uncorrected primary hyperparathyroidism.
    • When more frequent monitoring is performed, document the indication and rationale in the medical record.
    Documentation Required

    Document prescreen result and FRAX context when peripheral ultrasound used

    When a peripheral prescreen (e.g., pulse‑echo ultrasound/Bindex) is used, document the prescreen result, the fracture‑risk assessment context (such as FRAX), and whether the prescreen outcome led to avoidance of DXA or to referral for DXA.

    • Record the device used, measured Density Index or threshold applied, and the decision pathway (no DXA vs. refer for DXA).
    • Link prescreen findings to the overall fracture-risk assessment used for the patient (FRAX/QFracture).
    Documentation Required

    Document evidence when linking medications to BMD changes

    When citing medication-associated BMD effects, include primary study or meta-analysis details such as study population, measured sites, effect sizes, and confidence intervals as presented in the literature summaries.

    • Examples include SSRI studies and meta-analyses where lumbar spine BMD changes and subgroup effects were reported.
    • Document the evidence basis when using medication exposure to justify testing or management decisions.
    Documentation Required

    Document clinician review when AI/triage tools flag findings

    If AI/triage outputs (e.g., HealthVCF) are used to recall patients for further evaluation, document clinician review of the flagged imaging and the final diagnostic interpretation; AI output alone should not be relied upon for diagnosis.

    • HealthVCF provides triage/notification only and does not replace clinician review of the original CT.
    • Document that the final diagnosis was made by a clinician after review of the imaging study.
    Note
    Denial Risk

    Avoid investigational modalities — risk of noncoverage/denial

    Do not order bone mass measurements using DPA, DXL, SPA, pulse‑echo ultrasound (e.g., Bindex) for diagnostic/coverage purposes, cone beam CT, finite element analysis, skin autofluorescence (AGEs), or urinary phthalate testing for fracture‑risk assessment because these modalities are considered experimental/investigational and are not covered.

    • Explicitly listed investigational modalities: DPA, DXL, SPA, pulse‑echo ultrasound (Bindex), cone beam CT, finite element analysis, SAF-AGEs, and urinary phthalate testing.
    • Claims for these modalities may be denied as not covered per the policy’s investigational list.
    Denial Risk

    Avoid routine BMD testing in advanced CKD (stages 4–5)

    Do not routinely order BMD testing for patients with chronic kidney disease stages 4–5; routine BMD testing in CKD is of unclear utility and clinicians should avoid routine ordering in this population.

    • BMD testing does not reliably differentiate uremic bone diseases or predict fracture risk in CKD, limiting its clinical utility for therapeutic decisions.
    • Document specific clinical justification if BMD testing is performed in CKD patients.
    Denial Risk

    Use DXA as the diagnostic standard; CBCT not supported as substitute

    Use DXA as the standard diagnostic tool for BMD measurement and osteoporosis classification; cone beam CT is not supported as a diagnostic alternative in the cited review.

    • UpToDate and the policy identify DXA as the technology used for diagnostic classification in clinical practice.
    • CBCT is not mentioned as a diagnostic tool for osteoporosis in the referenced review and therefore is not an accepted substitute.
    Denial Risk

    AI triage outputs do not substitute for clinician diagnosis

    AI triage tools (e.g., HealthVCF) are for prioritization and do not replace clinician diagnosis; reliance on AI output alone for diagnostic evidence is inappropriate and may lead to noncoverage if used in place of clinician interpretation.

    • HealthVCF returns notifications to a worklist and is not diagnostic — the clinician must review the original study for final interpretation.
    • There are no peer-reviewed studies showing improved patient outcomes from HealthVCF; document clinician confirmation of findings.

    Background and Evidence Summary

    Background: Osteoporosis is characterized by low bone density and increased fracture risk in men and women. Post‑menopausal osteoporosis is related to estrogen decline. Dual‑energy X‑ray absorptiometry (DXA) is identified as the clinical standard for bone mass measurement, and older methods (DPA, SPA) have largely been replaced. Precision limits of densitometry mean that frequent (eg, annual) testing is generally not supported and longer intervals are usually required to reliably detect change.

    Definitions and Abbreviations

    inv-57: DEXA (DXA)
    DefinitionDual-energy X-ray absorptiometry (DEXA/DXA): current standard for bone mass measurement using an x-ray tube to generate dual-energy photons
    Typical usesAxial (spine, hip) and appendicular BMD measurement; diagnostic classification for osteoporosis; vertebral fracture assessment adjunct (VFA)
    NotesReplaced older methods (SPA, DPA) due to higher resolution and speed
    inv-58: VFA
    DefinitionVertebral fracture assessment (VFA): DXA-generated lateral imaging (morphometric x-ray absorptiometry) used as an adjunct to BMD to detect vertebral deformities
    PerformanceVFA showed good agreement with lateral X-rays in small pilot studies (high intra-/inter-reader reliability)
    Clinical useUsed to calculate FRAX scores and as adjunct to DXA for vertebral fracture detection
    inv-59: Bindex
    DefinitionBindex: handheld pulse‑echo ultrasound device measuring tibial cortical thickness to calculate a Density Index estimating hip BMD
    PerformanceStudies showed reasonable agreement with DXA; diagnostic thresholds developed and a Category III CPT code issued (2018)
    Intended rolePrescreen adjunct to fracture risk tools (eg, FRAX) to determine need for DXA referral
    inv-60: DXL (dual X‑ray and laser)/Calscan
    DefinitionDXL (dual X‑ray and laser)/Calscan: peripheral heel BMD technique combining two X‑ray beams with laser thickness measurement
    Study thresholdsCalscan T-score thresholds used in studies include upper -1.3 SD to exclude osteoporosis and lower -2.9 SD to predict osteoporosis
    PerformanceReported reproducibility and diagnostic accuracy favorable in small studies versus lumbar spine DXA
    inv-61: VFA (vertebral fracture assessment)
    DefinitionVFA (vertebral fracture assessment): lateral imaging derived from DXA for detection of vertebral deformities
    AgreementSmall pilot study showed high intra- and inter-observer reliability and good agreement with lateral X-rays
    Use caseCandidate for assessing radiographic damage in conditions like ankylosing spondylitis; further research needed
    inv-62: DXA
    DefinitionDXA: Dual-energy X-ray absorptiometry, the clinical standard for BMD measurement and diagnostic classification of osteoporosis
    AdvantagesHigher image resolution and speed than older methods (DPA, SPA); measures axial sites (spine, hip) relevant for fracture risk
    RoleUsed for screening, diagnosis, and monitoring response to osteoporosis therapy (monitoring response: DXA only)
    inv-63: FEA
    DefinitionFinite Element Analysis (FEA): CT-based computer modeling to estimate bone strength and predict fracture risk from imaging-derived geometry and density
    EvidenceCT-based FEA methods show strong associations with incident hip and vertebral fractures and may predict fractures as well as DXA in some studies
    Clinical limitationFEA cannot be used to diagnose osteoporosis, initiate therapy, or monitor therapy; primarily used in research pending standardization and thresholds
    inv-64: HR-pQCT
    DefinitionHR-pQCT: High-resolution peripheral quantitative computed tomography assessing bone microarchitecture and enabling FEA at peripheral sites
    UtilityMicro-architectural parameters from HR-pQCT improved fracture discrimination compared to areal BMD; adding FEA provided minimal extra benefit in one cohort
    Research roleIncreasingly used in research to characterize bone phenotypes and fracture risk; not established for routine clinical decision-making
    inv-65: Finite Element Analysis (FEA)
    DefinitionFinite Element Analysis (FEA): computer modeling using QCT/CT images to estimate bone strength (synonymous with CT-based FEA described elsewhere)
    Predictive performanceFEA measures (vertebral strength) associated with incident vertebral fractures and may outperform some CT-based aBMD metrics
    Clinical statusNot approved for diagnosis/therapy initiation; used primarily in research pending standardization
    inv-66: Radiological computer-assisted prioritization (HealthVCF)
    DefinitionRadiological computer-assisted prioritization (HealthVCF): FDA 510(k)-cleared AI software that analyzes chest/abdominal CTs to flag suspected vertebral compression fractures for clinician worklists
    LimitationsProvides triage/notification only; does not provide diagnostic confirmation and should not replace clinician review
    Regulatory noteHealthVCF received FDA 510(k) clearance in May 2020 (K192901)
    inv-67: Trabecular Bone Score (TBS)
    DefinitionTrabecular Bone Score (TBS): a texture index derived from lumbar spine DXA reflecting bone micro-architecture that can be incorporated into FRAX
    Performance noteAlternative lumbar vertebra combinations (eg, L1–L3) may improve fracture prediction versus traditional L1–L4 in some studies
    UseUsed as an adjunct to DXA for fracture risk evaluation, not as a standalone diagnostic test
    inv-68: Skin autofluorescence (SAF)
    DefinitionSkin autofluorescence (SAF): noninvasive measurement of tissue advanced glycation end-products (AGEs) using an AGE Reader
    AssociationsSAF correlates with AGE accumulation and is associated with lower BMD and higher prevalence of low bone density/osteoporosis in diabetes cohorts
    Clinical statusPromising research biomarker but requires further prospective validation before routine clinical use
    inv-69: SAF-AGEage = skin autofluorescence measure of AGEs adjusted by age (SAF-AGEs × age/100) as used in Liu et al (2022)
    DefinitionSAF-AGEage = skin autofluorescence measure of AGEs adjusted by age (SAF-AGEs × age/100) as used in Liu et al (2022)
    Study findingsHigher SAF-AGEage quartiles were associated with increased odds of low bone density/osteoporosis and higher incidence of major osteoporotic fractures in a T2DM cohort
    Clinical implicationMetric shows association with fracture outcomes in research but needs further validation for clinical decision-making
    inv-70: Urinary phthalate metabolites (e.g., MCPP, MCNP, MCOP, MEP, MnBP, MBzP) measured as exposure biomarkers
    AnalytesUrinary phthalate metabolites (examples: MCPP, MCNP, MCOP, MEP, MnBP, MBzP)
    Study contextMeasured as exposure biomarkers in Reeves et al (WHI sub-study) and examined for association with declines in hip and femoral neck BMD
    FindingsHigher concentrations of certain metabolites (eg, MCPP, MCNP) associated with greater percentage declines in total hip and femoral neck BMD over 3 years in HT nonusers
    inv-71: USPSTF screening guidance
    USPSTF referencePolicy references USPSTF screening guidance for postmenopausal women (USPSTF recommendation statements cited)
    Screening ageUSPSTF recommends screening women age >=65 and younger women at equivalent fracture risk as a 65-year-old white woman (per cited guidance)
    UseProvides screening guidance context referenced by the policy; local plan provisions determine coverage application
    inv-72: FDA device clearance
    DefinitionFDA device clearance: policy references FDA 510(k) summaries for devices used in bone densitometry
    ExampleHealthVCF (Zebra Medical Vision) 510(k) no. K192901 referenced (cleared May 2020)
    ImplicationRegulatory clearance may apply to triage/notification software but does not imply diagnostic replacement of clinician review